| Disease | THERE WERE SOME SPECTACULAR INDIVIDUAL RESPONSES IN BOTH GROUPS, BUT NO STATISTICALLY SIGNIFICANT DIFFERENCES, AND NO DIFFERENCES IN SIDE-EFFECTS.
QUESTIONNAIRE WAS RECORDED AT -1,0,1,3,6,9 AND 12 WEEKS, AND A NON-BLIND FOLLOW-UP FOR A FURTHER 6 WEEKS ON GINKGO. HAMILTON ANXIETY AND DEPRESSION RATINGS WERE MADE AT 0,6 AND 12 WEEKS AND SIMPLE GLOBAL ASSESMENTS OF ALERTNESS AND MEMORY.
EFFICACY ANALYSIS WAS CARRIED OUT ON 8 MALES AND 5 FEMALES ON PLACEBO AND 6 MALES AND 5 FEMALES ON GINKGO, COMPLETING THE FULL 12 WEEKS OF TREATMENT. NOT INCLUDED WERE 3 SUBJECTS WHO DROPPED OUT AFTER6 WEEKS. AVALIDATED SEX(GENDER)-ORIENTATED
A TRIPLE-BLIND (INVESTIGATOR,PATIENT,STATISTICIAN), RANDOMIZED, PLACEBO-CONTROLLED, TRIAL OF GINKGO BILOBA 240 MG DAILY WAS CARRIED OUT. FOLLOWING A 1 WEEK CONTROL, IT WAS GIVEN TO 24 PATIENTS WITH SEXUAL IMPAIRMENT DUE TO ANTIDEPRESSANT DRUGS. |